Blood Coagulation Factor Viii, Ahf Patents (Class 530/383)
  • Patent number: 9577311
    Abstract: The invention relates to an HF resonator comprising a cylindrical cavity made of a dielectric material. An inner face of the cavity has an electrically conductive coating which is divided into a first inner coating and a second inner coating by an electrically insulating gap that encircles a lateral face of the cavity in an annular manner. An outer face of the cavity has an electrically conductive first outer coating and an electrically conductive second outer coating. The first outer coating and the second outer coating are electrically insulated from each other. The HF resonator comprises a device that is provided for applying a high-frequency electric voltage between the first outer coating and the second outer coating.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: February 21, 2017
    Assignee: Siemens Aktiengesellschaft
    Inventors: Michael Back, Oliver Heid, Michael Kleemann
  • Patent number: 9488625
    Abstract: The present specification discloses methods of eluting a protein from a chromatography column.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: November 8, 2016
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Martin Felgenhauer, Helmut Maierhofer, Dominique Mison, Arnaud Desponds
  • Patent number: 9453045
    Abstract: A process of purifying the Growth Factor Protein G-CSF (Granulocyte Colony Stimulating Factor) in a purification sequence employing chromatography, comprising binding the G-CSF to Capto MMC™, which is a multimodal resin that comprises a negatively charged 2-(benzoylamino) butanoic acid ligand, at a pH from 4 to 6.2; and eluting the G-CSF at a pH greater than 6.3.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: September 27, 2016
    Assignee: OCTAPHARMA AG
    Inventors: Gustav Gilljam, Stefan Winge, Maya Tiemeyer
  • Patent number: 9359397
    Abstract: The present invention provides a method for manufacturing a virus-free protein drug, comprising (a) a filtration step of filtering a virus-containing protein solution through a small-pore size virus removal membrane to obtain a virus-free protein solution, the filtration step (a) comprising (q) a low-pressure filtration step of filtering the solution through the small-pore size virus removal membrane at a filtration pressure of 0.30 kgf/cm2 or lower to obtain the virus-free protein solution, wherein the solution prior to filtration in the low-pressure filtration step (q) has a pH (X) and a salt ionic strength (Y (mM)) that satisfy the following equations 1 and 5: 0?Y?150X?590 (Equation 1) and 3.5?X?8.0 (Equation 5) or the following equations 4 and 5: Y=0 (Equation 4) and 3.5?X?8.0 (Equation 5).
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: June 7, 2016
    Assignee: ASAHI KASEI MEDICAL CO., LTD.
    Inventors: Tomoko Hongo, Hirohisa Hayashida
  • Patent number: 9328338
    Abstract: The invention relates to purification of an intact, non-degraded macromolecule from a biological mixture comprising the macromolecule in the presence of its lytic enzyme. The method comprises providing the biological mixture as a heterogeneous mixture comprising the lytic enzyme, at least partially, in soluble form and the macromolecule, at least partially, in non-soluble form; batch-wise contacting the heterogeneous mixture with an immobilized inhibitor of the lytic enzyme; increasing the solubility of the macromolecule in the mixture; and removing the immobilized inhibitor from the mixture.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: May 3, 2016
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Roberto Meidler, Nina Raver-Shapira, Liliana Bar, Oleg Belyaev, Israel Nur
  • Patent number: 9296799
    Abstract: A process for isolation and purification of a target protein by chromatography wherein the chromatography removes or depletes prions (PrPSC), comprising the steps of contacting a potentially PrPSC contaminated sample comprising a target protein with a multimodal chromatographic material; setting buffer conditions so that the target protein is bound to the multimodal chromatographic material and whereas PrPSC is not binding to the multimodal chromatographic material; followed by elution of the target protein. a process for isolation and purification of a target protein free of prion protein (prpSC).
    Type: Grant
    Filed: August 25, 2008
    Date of Patent: March 29, 2016
    Assignee: OCTAPHARMA AG
    Inventors: Gustav Gilljam, Mats Jernberg, Stefan Winge, Andrea Neisser-Svae
  • Patent number: 9173248
    Abstract: An apparatus and method for thawing a product. The apparatus includes a heating chamber, and an electrical control unit. The heating chamber includes a product chamber that holds a product, at least one heating element, each heating element emitting infrared energy in a direction of the product, and at least one temperature sensor, each temperature sensor measuring a surface temperature of the product. The electrical control unit includes a processor that controls and monitors said at least one heating element, and said at least one temperature sensor to raise a temperature of the product from an initial temperature to a set-point temperature, a connection to each heating element, and a connection to each temperature sensor.
    Type: Grant
    Filed: March 14, 2011
    Date of Patent: October 27, 2015
    Assignee: Products Support, Inc.
    Inventor: Rodney Warren Baker
  • Patent number: 9050318
    Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: December 6, 2010
    Date of Patent: June 9, 2015
    Assignee: Biogen Idec Hemophilia Inc.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters
  • Publication number: 20150147345
    Abstract: This document relates to conjugates of a biologically active molecule or a derivative thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.
    Type: Application
    Filed: June 12, 2013
    Publication date: May 28, 2015
    Inventor: Marek Kwiatkowski
  • Patent number: 9034822
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: May 19, 2015
    Assignee: Boehringer Igelheim International GmbH
    Inventors: Joanne Van Ryn, John Edward Park, Norbert Hauel, Ulrich Kunz, Tobias Litzenburger, Keith Canada, Sanjaya Singh, Alisa Waterman
  • Patent number: 9018166
    Abstract: The present invention relates to conjugated Factor VIII variants. The present invention in particular relates to conjugated FVIII variants comprising different polymeric groups as well as use thereof.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: April 28, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Carsten Behrens, Jens Buchardt, Magali Zundel
  • Publication number: 20150093370
    Abstract: The present invention provides albumin-binding probes capable of reversibly linking to short-lived amino-containing drugs and non-covalently associating with albumin in-vivo, thereby converting said drugs into inactive reactivable prodrugs having prolonged lifetime in-vivo. The invention further provides conjugates of said probes with amino-containing drugs, as well as pharmaceutical compositions and uses thereof.
    Type: Application
    Filed: December 9, 2014
    Publication date: April 2, 2015
    Inventors: Yoram SHECHTER, Matityahu FRIDKIN
  • Publication number: 20150087593
    Abstract: The invention describes factor VIII molecules with reduced capacity to elicit activation of NKT cells for use in the treatment of congenital and/or acquired haemophilia A and in bleeding disorders. Said factor VIII molecule is obtainable by: a. identification of at least one NKT cell epitope wherein said epitope comprises hydrophobic aminoacid residues in position P1 and/or P7 b. modification of said epitope(s) by eliminating at least one hydrophobic aminoacid residues in position P1 and/or P7, substituting at least one hydrophobic aminoacid residue in position P1 and/or P7 with a non-hydrophobic residue, or adding a non-hydrophobic residue in position P1 and/or P7.
    Type: Application
    Filed: May 21, 2013
    Publication date: March 26, 2015
    Inventor: Jean-Marie Saint-Remy
  • Publication number: 20150086524
    Abstract: Methods and dosage formulations are provided for subcutaneous administration in which therapeutic agents are modified to increase the hydrophilicity and molecular dimensions in relation to the native state of the therapeutic agent, in which the Cmax:Caverage ratio is lower than the Cmax:Caverage ratio of the agent when delivered intravenously.
    Type: Application
    Filed: April 16, 2013
    Publication date: March 26, 2015
    Applicant: CANTAB BIOPHARMACEUTICALS PATENTS LIMITED
    Inventors: William Henry, Richard Wolf-Garraway, John Charles Mayo, Michael James Earl
  • Publication number: 20150080309
    Abstract: The present invention relates to VWF compounds as well as compositions suitable for treatment of blood clotting diseases.
    Type: Application
    Filed: March 13, 2013
    Publication date: March 19, 2015
    Inventors: Gert Bolt, Ditte M. Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Jens J. Hansen
  • Patent number: 8969524
    Abstract: The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4+ T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: March 3, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Katharina Nora Steinitz, Paula Maria Wilhelmina van Helden, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich
  • Publication number: 20150045303
    Abstract: The present invention relates to pharmaceutical compositions suitable for treatment of haemophilia.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 12, 2015
    Inventors: Gert Bolt, Ditte M. Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Peder L. Noerby, Jens J. Hansen
  • Publication number: 20150037301
    Abstract: The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed.
    Type: Application
    Filed: October 19, 2014
    Publication date: February 5, 2015
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Philip J. Fay, Hironao Wakabayashi
  • Publication number: 20150038421
    Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.
    Type: Application
    Filed: June 27, 2014
    Publication date: February 5, 2015
    Inventors: Volker SCHELLENBERGER, Pei-Yun Chang, Fatbardha Varfaj, John Kulman, Tongyao Liu, Garabet G. Toby, Haiyan Jiang, Robert Peters, Deping Wang, Baisong Mei, Joshua Silverman, Chia-Wei Wang, Benjamin Spink, Nathan Geething
  • Patent number: 8945897
    Abstract: The invention relates to materials and methods of conjugating a water soluble fatty acid derivative to a therapeutic protein comprising contacting the therapeutic protein with an activated water soluble fatty acid derivative under conditions that allow conjugation.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: February 3, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Juergen Siekmann, Richard Sheinecker, Hanspeter Rottensteiner, Peter Turecek
  • Patent number: 8940876
    Abstract: The present disclosure relates to a method for preparing recombinant glycoproteins with high sialic acid content. More specifically, for UDP-GlcNAc 2-epimerase/ManNAc kinase (GNE/MNK) enzyme where point mutation was induced by substituting arginine at position 263 by leucine only or by further substituting arginine at position 266 by glutamine, epimerase activity is constantly maintained, and overexpressed cells thereof experience an increase in intracellular cytidine monophosphate (CMP)-sialic acid content, irrespective of CMP-sialic acid concentration.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: January 27, 2015
    Assignee: Korea Advanced Institute of Science and Technology
    Inventors: Jung Hoe Kim, Young Dok Son, Jin Young Hwang, Yeon Tae Jeong
  • Publication number: 20150023946
    Abstract: The present invention relates to pharmaceutical preparations comprising Factor VIII, a sulfated glycosaminoglycan and a hyaluronidase for the non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders. The invention further relates to the combined use of a Factor VIII, a sulfated glycosaminoglycan and a hyaluronidase for the treatment and prevention of bleeding disorders, and to a method for increasing the bioavailability after non-intravenous administration of Factor VIII by co-adminstration of a sulfated glycosaminoglycan and a hyaluronidase.
    Type: Application
    Filed: October 18, 2012
    Publication date: January 22, 2015
    Applicant: CSL BEHRING GMBH
    Inventors: Sabine Zollner, Hubert Metzner
  • Publication number: 20150023959
    Abstract: The present invention provides a VWF fragment comprising the D? domain and D3 domain of VWF, a chimeric protein comprising the VWF fragment and a heterologous moiety, or a chimeric protein comprising the VWF fragment and a FVIII protein and methods of using the same. A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein. By preventing or inhibiting binding of endogenous VWF to the FVIII, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.
    Type: Application
    Filed: January 12, 2013
    Publication date: January 22, 2015
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Ekta Seth Chhabra, Tongyao Liu, Robert T. Peters, Haiyan Jiang
  • Publication number: 20150018525
    Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.
    Type: Application
    Filed: July 23, 2014
    Publication date: January 15, 2015
    Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt
  • Publication number: 20150010494
    Abstract: A method of preparing an oxidised polysaccharide-protein conjugate by oxidising a polysaccharide with an oxidising agent to form an oxidised polysaccharide and combining such oxidised polysaccharide with a protein. The oxidised polysaccharide is reacted with a protein to form a composition comprising a conjugate wherein the oxidised polysaccharide and the protein are conjugated via one or more imine bonds and wherein the oxidised polysaccharide comprises essentially no alpha-hydroxy aldehyde units. The conjugate may be used to provide sustained or latent activity of the protein.
    Type: Application
    Filed: September 22, 2014
    Publication date: January 8, 2015
    Inventors: Gord Adamson, David Bell, Steven Brookes
  • Publication number: 20150005473
    Abstract: Disclosed is an expression vector system for variants of coagulation Factor VIII (FVIII) and von Willebrand Factor (vWF). In detail, mutant vWF the size of which is significantly reduced by deleting exons but which has remarkably increased FVIII stabilizing and activating efficiency, and an expression vector system useful for the treatment of hemophilia which is capable of expressing the same along with FVIII are disclosed. Use of the mutant vWF with a reduced size enables effective expression of FVIII in a viral vector and significantly enhanced FVIII activity. Further, the viral vector may be effectively used to treat hemophilia through gene therapy.
    Type: Application
    Filed: May 30, 2014
    Publication date: January 1, 2015
    Applicant: Korea University Industrial & Academic Collaborative Foundation
    Inventors: Sang Yun CHOI, Sang Won PARK
  • Publication number: 20150004667
    Abstract: The present invention is generally directed to functionalized graphene substrates, methods of making such substrates and methods of using such substrates. In one aspect, the present invention provides a graphene substrate. The substrate comprises edge and non-edge regions, and organic or inorganic molecules are bound to the edge regions of the substrate. The organic or inorganic molecules are present on the substrate edges at a population greater than about one molecule per 10,000 nm.
    Type: Application
    Filed: May 23, 2014
    Publication date: January 1, 2015
    Applicant: NANOTECH BIOMACHINES, INC.
    Inventors: Jeffrey Alan McKinney, William Emerson Matinez
  • Publication number: 20140357564
    Abstract: The present invention relates to a polypeptide comprising a modified von Willebrand Factor (VWF) having a higher Factor VIII binding affinity than non-modified VWF, its pharmaceutical use and method of its preparation.
    Type: Application
    Filed: February 14, 2013
    Publication date: December 4, 2014
    Inventors: Stefan Schulte, Thomas Weimer, Kay Hofmann
  • Publication number: 20140357565
    Abstract: Provided herein are methods and compositions for producing Factor VIII proteins. Such methods include introducing into a cell a nucleic acid molecule encoding a Factor VIII protein operably linked to a promoter, wherein the promoter is characterized by the ability to produce commercially viable Factor VIII protein; and incubating the cell under conditions for producing commercially viable Factor VIII protein. Also provided are nucleic acid molecules which encode a Factor VIII protein operably linked to a Chinese hamster elongation factor 1-a (CHEF1) promoter, which may be used in the methods provided herein.
    Type: Application
    Filed: August 13, 2014
    Publication date: December 4, 2014
    Inventors: Randal J. KAUFMAN, Steven W. Pipe, Michael GRIFFITH
  • Patent number: 8889831
    Abstract: Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: November 18, 2014
    Assignee: Nektar Therapeutics
    Inventors: Mary J. Bossard, Michael D. Bentley, Ping Zhang
  • Publication number: 20140335051
    Abstract: The synergistic biomolecule-polymer conjugates are the long-acting, in vivo controlled continuous-release and hybrid synergy systems of biomolecules that provide increased biological activities and enhanced pharmacological properties for achieving greater therapeutic efficacies.
    Type: Application
    Filed: July 28, 2014
    Publication date: November 13, 2014
    Applicant: PEG Biosciences, Inc.
    Inventor: Chyi Lee
  • Publication number: 20140329994
    Abstract: The present invention is directed to branched reactive water-soluble polymers comprising at least two polymer arms, such as poly(ethylene glycol), attached to a central aliphatic hydrocarbon core molecule through heteroatom linkages. The branched polymers bear at least one functional group for reacting with a biologically active agent to form a biologically active conjugate. The functional group of the branched polymer can be directly attached to the aliphatic hydrocarbon core or via an intervening linkage, such as a heteroatom, -alkylene-, —O-alkylene-O—, -alkylene-O-alkylene-, -aryl-O—, —O-aryl-, (—O-alkylene-)m, or (-alkylene-O—)m linkage, wherein m is 1-10.
    Type: Application
    Filed: July 17, 2014
    Publication date: November 6, 2014
    Inventors: Michael D. Bentley, Xuan Zhao, Xiaoming Shen, William D. Battle, III
  • Publication number: 20140315815
    Abstract: The present invention relates to pharmaceutical preparations comprising one or more Factor VIII and a sulfated glycosaminoglycan for increasing the bioavailability of Factor VIII upon non-intravenous administration. The invention further relates to the combined use of Factor VIII and a sulfated glycosaminoglycan for the treatment and prevention of bleeding disorders, whereby the bioavailability of Factor VIII is increased, and to a method for increasing the bioavailability after non-intravenous administration of Factor VIII by coadminstration of a sulfated glycosaminoglycan.
    Type: Application
    Filed: October 18, 2012
    Publication date: October 23, 2014
    Inventors: Hubert Metzner, Sabine Zollner
  • Patent number: 8865868
    Abstract: The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing the conjugated proteins which contain the steps of reacting a protein or glycoprotein, such as factor VIIa or human growth hormone, with a water insoluble albumin binder in the presence of an optionally substituted cyclodextrin molecule, to pharmaceutical compositions comprising the protein conjugates and to the use of the protein conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: October 21, 2014
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Carsten Behrens, Patrick William Garibay, Søren Østergaard, Henrik Sune Andersen, Nils Langeland Johansen, Bernd Peschke, Sonja Bak
  • Patent number: 8859731
    Abstract: A method of selectively introducing a substituent into a protein proximal to a binding site on the protein for a homing peptide, comprising: (a) contacting the protein with a compound comprising a homing peptide having the ability to bind to the binding site of the protein; and (b) allowing a moiety on the protein proximal to the binding site to react with the compound comprising the homing peptide, thereby to transfer the substituent G onto the protein.
    Type: Grant
    Filed: April 12, 2011
    Date of Patent: October 14, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Mikael Kofod-Hansen, Henning Ralf Stennicke, Soeren Oestergaard, Henrik Oestergaard
  • Publication number: 20140295521
    Abstract: A new use of a molecule comprising at least one moiety which is a biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal is provided, for preparation of a medicament which elicits no or a reduced immune response upon administration to the mammal, as compared to the immune response elicited upon administration to the mammal of the biologically active protein per se. Also provided is a method of reducing or eliminating the immune response elicited upon administration of a biologically active protein to a human or non-human mammal, which comprises coupling the polypeptide to at least one moiety capable of binding to a serum albumin of the mammal.
    Type: Application
    Filed: January 21, 2014
    Publication date: October 2, 2014
    Applicant: AFFIBODY AB
    Inventor: Nina Herne
  • Publication number: 20140294762
    Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.
    Type: Application
    Filed: April 7, 2014
    Publication date: October 2, 2014
    Applicant: Novo Nordisk A/S
    Inventors: Shawn DeFrees, David A. Zopf, Robert J. Bayer, David James Hakes, Caryn L. Bowe, Xi Chen
  • Publication number: 20140274903
    Abstract: This invention relates to novel compounds, methods for selective chemical conjugation of protractor molecules and the use thereof for diagnostic and/or therapeutic purposes.
    Type: Application
    Filed: April 29, 2014
    Publication date: September 18, 2014
    Applicant: NOVO NORDISK HEALTHCARE AG
    Inventors: Carsten Behrens, Patrick W. Garibay, Magali Zundel, Niels Kristian Klausen, Soeren Bjoern
  • Patent number: 8835388
    Abstract: The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: September 16, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Friedrich Scheiflinger, Peter Turecek, Jueren Siekmann
  • Patent number: 8828676
    Abstract: The present invention relates, in general, to methods for detecting and quantitating plasma-derived protein and recombinant protein in a sample based on the difference in protein glycosylation, when the plasma protein and the recombinant protein are essentially the same protein.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: September 9, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Alfred Weber, Peter Turecek, Hans-Peter Schwarz
  • Publication number: 20140249086
    Abstract: The present invention relates to a method for increasing the stability of a Factor VIII molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the Factor VIII molecule into a first fragment comprising essentially the A1 domain and the A2 domain and a second fragment comprising essentially the A3 domain, the C1 domain and the C2 domain throughout manufacturing of the Factor VIII molecule. The invention further pertains to a method for improving the bioavailability of Factor VIII after intravenous and non-intravenous injection.
    Type: Application
    Filed: October 18, 2012
    Publication date: September 4, 2014
    Applicant: CSL Limited
    Inventors: Carsten Horn, Sabine Zollner, Hubert Metzner, Stefan Schulte
  • Patent number: 8816054
    Abstract: Factor VIII variants and methods of use thereof are disclosed.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: August 26, 2014
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Valder Arruda, Rodney M. Camire, Nicholas Iacobelli
  • Patent number: 8809501
    Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: August 19, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
  • Publication number: 20140227766
    Abstract: Materials and methods for use of constrained cohydration agents in the purification of biological materials such as antibodies, viruses, cells, and cellular organelles in connection with convective chromatography, fluidized bed or co-precipitation applications.
    Type: Application
    Filed: June 1, 2012
    Publication date: August 14, 2014
    Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventor: Peter Stanley Gagnon
  • Publication number: 20140221611
    Abstract: It is an object of the present invention to provide novel binding molecules for factor VIII and factor VIII-like proteins. Preferred binding molecules of the present invention exhibit not only distinct characteristics for binding of the target factor VIII polypeptides but also specific and desirable characteristics for release (elution) of the target polypeptides. Especially preferred binding molecules according to the invention are short polypeptide sequences, characterized by a stable loop structure.
    Type: Application
    Filed: August 14, 2013
    Publication date: August 7, 2014
    Applicant: DYAX CORP.
    Inventors: Jinan Yu, M. Daniel Potter, Brian D. Kelley, Jeffrey S. Deetz, James E. Booth
  • Publication number: 20140221618
    Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.
    Type: Application
    Filed: April 15, 2014
    Publication date: August 7, 2014
    Inventors: Richard Feldman, Ji-Yun Kim, Haiyan Jiang, Kirk Mclean, Junliang Pan, Glenn Pierce, James Wu, Xiao-Yan Zhao
  • Publication number: 20140206844
    Abstract: Described is a method for isolating multiple blood products from a single starting material. Isolation of multiple blood products from a single starting material maximizes the efficiency of blood product isolation. In the present invention, one or more blood products are isolated from a blood product material previously depleted of inter-alpha inhibitor protein (I?Ip). This method provides new paths for increasing the efficiency of isolating blood components and providing pharmaceutically acceptable forms of those components.
    Type: Application
    Filed: January 16, 2014
    Publication date: July 24, 2014
    Applicant: ProThera Biologics
    Inventor: Yow-Pin LIM
  • Publication number: 20140193880
    Abstract: The present invention relates to a modified and optimized Factor VIII or Factor IX nucleic acid for inclusion in a chimeric virus vector. Use of such vector can be used for treatment of hemophilia.
    Type: Application
    Filed: January 17, 2014
    Publication date: July 10, 2014
    Applicant: Asklepios Biopharmaceutical, Inc.
    Inventor: RICHARD J. SAMULSKI
  • Patent number: 8765665
    Abstract: A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: July 1, 2014
    Assignees: Baxter International Inc., University of Connecticut
    Inventors: Marc Besman, Erik Bjornson, Feroz Jameel, Ramesh Kashi, Michael Pikal, Serguei Tchessalov, John Carpenter
  • Patent number: 8759293
    Abstract: The present invention relates to methods, compositions and kits for preparing FVIII and employing same. Also provided are vWF polypeptides and nucleic acid molecules encoding same.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: June 24, 2014
    Assignee: Grifols Therapeutics Inc.
    Inventor: Thomas Barnett